Oncolytics Biotech, Inc. (ONCY)

Current

- (-)

After Hours

Rating & Fair Value

Rating Premium

Fair Value Premium

Institutional Holdings

Financial Strength

Sustainable Growth

Industry Comparison

Management & Equity

Analyst Opinion

Leverage & Liquidity

Fundamental Variables

Rating Performance

FV Performance

About

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

CEO

Matthew C. Coffey

Employees

Industry

Sector

Headquarters

Calgary

Exchange

NASDAQ

Website

http://www.oncolyticsbiotech.com

Summary Stats

Market Cap

111M

Revenue

Net Income

EPS

$0.00

Price-to-Earnings

Price-to-Book

Debt-to-Equity

News

Analyst Ratings

Price targets projected by 4 analysts

High

$11.00

Average

$8.79

Low

$6.00

Ratings calculated by 3 analysts

Buy

Hold

Sell

Last Dividend

Amount

Dividend Date

Frequency

Dividend Yield

Earnings

Most Recent Earnings

Nov

Last Earnings for Q3 2022

Last Earnings

Above by $0.02

Actual

-$0.06 +25.0%

Consensus

-0.08

Report Date

November 7, 2022

Year Ago

-0.071

Year Ago Change %

Up 15%

Actual vs Estimates

xxx

Upcoming Estimates Unavailable

Expected EPS
-

Actual EPS
-

Competitors

Æterna Zentaris, Inc.

AEZS

AVEO Pharmaceuticals, Inc.

AVEO

Bristol-Myers Squibb Co.

BMY

Eli Lilly & Co.

LLY

Mirati Therapeutics, Inc.

MRTX

Sophiris Bio Inc

SPHS

Teva Pharmaceutical Industries Ltd.

TEVA